Julie Tierney, JD

Julie Tierney is a principal at Leavitt Partners based in Washington, D.C. She has over 25 years of experience in FDA law and policy. Tierney helps life sciences companies, patient organizations, and others understand and develop regulatory and engagement strategies and advance policy solutions for complex issues related to product development, review, and marketing. Before coming to Leavitt Partners, Julie served in a number of senior roles at the U.S. Food and Drug Administration that leveraged her substantial legal, policy and operational expertise. She served as the FDA chief of staff, during which time she managed multiple public health crises and oversaw the daily management of the agency and major cross-cutting agency activities. Julie most recently served as deputy director of FDA’s Center for Biologics Evaluation and Research, where she led the center’s policy and legislative engagements related to complex biologics such as cell and gene therapies, vaccines, and blood products, cross-agency rare disease efforts, including the launch of the FDA Rare Disease Innovation Hub, and other strategic initiatives.